Tarsus Pharmaceuticals Inc
For the period ended Mar 31, 2024. Filed May 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 8, 2024
TARS$73.83+4.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Revenues: | ||
| Product sales, net | $24,720 | $— |
| License fees and collaboration revenue | 2,894 | 2,500 |
| Total revenues | 27,614 | 2,500 |
| Operating expenses: | ||
| Cost of sales | 1,654 | — |
| Research and development | 12,066 | 12,356 |
| Selling, general and administrative | 51,578 | 15,096 |
| Total operating expenses | 65,298 | 27,452 |
| Loss from operations before other income (expense) | (37,684) | (24,952) |
| Other income (expense): | ||
| Interest income | 3,117 | 2,293 |
| Interest expense | (983) | (684) |
| Other income, net | 605 | 6 |
| Unrealized loss on equity investments | (585) | (65) |
| Change in fair value of equity warrants issued by licensee | (201) | (17) |
| Total other income, net | 1,953 | 1,533 |
| Net loss | $(35,731) | $(23,419) |
| Other comprehensive loss: | ||
| Unrealized (loss) gain on marketable securities and cash equivalents | (61) | 4 |
| Comprehensive loss | $(35,792) | $(23,415) |
| Net loss per share, basic and diluted | $(1.01) | $(0.88) |
| Weighted-average shares outstanding, basic and diluted | 35,300,655 | 26,742,023 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.